Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine

Published: Monday, December 03, 2012
Last Updated: Monday, December 03, 2012
Bookmark and Share
Interim results of the phase I/IIa clinical study revealed a good safety and tolerability profile for the VAC-3S immunotherapeutic vaccine, which was the primary endpoint of the study performed in two AP-HP reference clinical centers in Paris, France, at Pitié Salpêtrière and Cochin Hospitals.

InnaVirVax has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

A phase I/IIa dose escalation study was performed in 24 patients living with HIV whose CD4 T-lymphocyte levels were higher than 200/mm3 and who were under antiretroviral therapy [ART].

The treatment was administered in 3 injections at 4-week intervals. The primary endpoint of this study was to assess the safety and tolerability of VAC-3S, four weeks after the third injection.

Secondary endpoints included an evaluation of the immune response, the long-term safety of the treatment and the monitoring of different biological markers of infection (including viral load and the CD4 T-lymphocyte count).

The study was carried out under double-blinded conditions in two AP-HP (Paris Public Hospitals System) academic reference clinical centers at Hospital de la Pitié Salpêtrière and Hospital Cochin.

The results showed that VAC-3S was well tolerated, thus meeting the primary endpoint of the study. Full results of this study will be presented at an international medical conference.

Professor Christine Katlama, in the Infectious and Tropical Diseases Department at Hôpital de la Pitié Salpêtrière and principal investigator for the study, stated: "These results are important insofar as the primary study endpoint has been achieved. A treatment regimen consisting of three injections of VAC-3S was thus well tolerated. This is a key stage in the clinical development of this immunotherapy, which will supplement the antiretroviral therapies that are currently available."

Professor Odile Launay, Coordinating Physician at the Cochin-Pasteur Vaccinology Clinical Investigation Center at Hôpital Cochin, and joint investigator for the study, added: "Observation of the safety of VAC-3S after three injections is very encouraging in terms of the future development prospects for this immunotherapy".

Dr Shahin Gharakhanian, acting Chief Medical Officer of InnaVirVax who is based in the Cambridge Innovation Center (Cambridge, Massachusetts, USA), went on: "We are looking forward to analyzing these results in detail in terms of the full set of endpoints.

We are also actively preparing the next stage, which will involve submission of an application for a Phase II clinical study that takes account of the regulatory requirements for our type of product. We are also in discussion with US and European experts, and thus are working closely with clinicians in major centers.

Joël Crouzet, CEO of InnaVirVax concluded: "These clinical data obtained with the candidate immunotherapy VAC-3S are encouraging. The promising findings we are revealing today confirm the validity of our strategy, which aims to protect a patient's immune system. VAC-3S may therefore constitute an innovation for HIV patients by preserving their immune system".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InnaVirVax Strengthens Patent Protection of VAC-3S Immunotherapy
The Company reaches a new stage of development with the filing of a new European patent application for VAC-3S aimed at protecting the immune system of patients infected with HIV-1.
Wednesday, December 26, 2012
InnaVirVax Announces the Launch of the First Clinical Trial on VAC-3S
This trial is supported by a grant from the “OSEO” French Innovation Agency.
Tuesday, March 06, 2012
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!